Skip to main content

ORIGINAL RESEARCH article

Front. Genet.
Sec. Cancer Genetics and Oncogenomics
Volume 15 - 2024 | doi: 10.3389/fgene.2024.1509342

BIRC5 as a Prognostic and Diagnostic Biomarker in Pan-Cancer: An Integrated Analysis of Expression, Immune Subtypes, and Functional Networks

Provisionally accepted
Guoyu Li Guoyu Li 1Yanghao Wang Yanghao Wang 2Wei-zhou Wang Wei-zhou Wang 2Guodong Lv Guodong Lv 3Xiang Li Xiang Li 3Jingying Wang Jingying Wang 3Xiuyu Liu Xiuyu Liu 3Daolang Yuan Daolang Yuan 3Shoujun Deng Shoujun Deng 4Dingyun You Dingyun You 3,5*
  • 1 Yunnan Cancer Hospital, Kunming, Yunnan Province, China
  • 2 The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China
  • 3 Kunming Medical University, Kunming, Yunnan Province, China
  • 4 Yan'an Hospital Affiliated To Kunming Medical University, Kunming, Yunnan Province, China
  • 5 Affiliated Stomatology Hospital of Kunming Medical University, Kunming, China

The final, formatted version of the article will be published soon.

    BIRC5 (Survivin), a critical anti-apoptotic protein, is overexpressed in numerous cancers and plays an essential role in promoting tumor cell proliferation and resistance to treatment. However, its expression patterns across different cancer types, as well as its associations with clinical features and the immune microenvironment, have yet to be comprehensively characterized. In this study, we performed an extensive analysis of BIRC5 expression using data from TCGA and TISIDB to assess its diagnostic and prognostic potential across 33 cancer types. ROC curve analysis demonstrated BIRC5's strong diagnostic utility, with AUC values exceeding 0.9 in several cancer types. Survival analyses further indicated that high BIRC5 expression is associated with poor prognosis in multiple cancers. Additionally, BIRC5 showed a strong association with the tumor immune microenvironment, and its role in cell cycle regulation and cancer progression was further supported by protein-protein interaction (PPI) network analysis. Functional experiments in lung adenocarcinoma (LUAD) revealed that BIRC5 upregulation enhances cell proliferation, migration, and invasion, while its knockdown suppresses these activities. In conclusion, BIRC5 is a promising diagnostic and prognostic biomarker for various cancers and represents a potential target for therapeutic intervention.

    Keywords: BIRC5, Cancer prognosis, Tumor immune microenvironment, Diagnostic biomarker, Lung Adenocarcinoma

    Received: 10 Oct 2024; Accepted: 19 Nov 2024.

    Copyright: © 2024 Li, Wang, Wang, Lv, Li, Wang, Liu, Yuan, Deng and You. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Dingyun You, Kunming Medical University, Kunming, 650500, Yunnan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.